BR112022021521A2 - Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp) - Google Patents

Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp)

Info

Publication number
BR112022021521A2
BR112022021521A2 BR112022021521A BR112022021521A BR112022021521A2 BR 112022021521 A2 BR112022021521 A2 BR 112022021521A2 BR 112022021521 A BR112022021521 A BR 112022021521A BR 112022021521 A BR112022021521 A BR 112022021521A BR 112022021521 A2 BR112022021521 A2 BR 112022021521A2
Authority
BR
Brazil
Prior art keywords
parp
cancer
polymerase
inhibitors
poly
Prior art date
Application number
BR112022021521A
Other languages
English (en)
Inventor
Bhuniya Debnath
Viswanadha Srikant
Swaroop Merikapudi Gayatri
Kumar Venkata Satya Vakkalanka Swaroop
Original Assignee
Rhizen Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Ag filed Critical Rhizen Pharmaceuticals Ag
Publication of BR112022021521A2 publication Critical patent/BR112022021521A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

COMPOSTOS INOVADORES ÚTEIS COMO INIBIDORES DE POLI(ADPRIBOSE)POLIMERASE (PARP). A presente invenção fornece novos inibidores de poli(ADP-ribose)polimerase (PARP), métodos de preparação dos mesmos, composições farmacêuticas que contêm os mesmos e métodos para o tratamento, a prevenção e/ou o alívio de doenças ou distúrbios mediados por PARP com o uso dos mesmos. Em particular, os compostos descritos neste documento são úteis para o tratamento de carcinoma da mama, câncer ovariano, carcinoma do fígado, carcinoma do pulmão, câncer de pulmão de células pequenas, câncer esofágico, câncer de vesícula biliar, câncer pancreático e câncer de estômago.
BR112022021521A 2020-04-28 2021-04-23 Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp) BR112022021521A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041018149 2020-04-28
IN202041047713 2020-11-02
PCT/IB2021/053382 WO2021220120A1 (en) 2020-04-28 2021-04-23 Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors

Publications (1)

Publication Number Publication Date
BR112022021521A2 true BR112022021521A2 (pt) 2023-01-24

Family

ID=75870674

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021521A BR112022021521A2 (pt) 2020-04-28 2021-04-23 Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp)

Country Status (14)

Country Link
US (1) US20230234938A1 (pt)
EP (1) EP4143182A1 (pt)
JP (1) JP2023524212A (pt)
KR (1) KR20230002487A (pt)
CN (1) CN115485271A (pt)
AU (1) AU2021262569A1 (pt)
BR (1) BR112022021521A2 (pt)
CA (1) CA3176206A1 (pt)
CL (1) CL2022002966A1 (pt)
CO (1) CO2022016819A2 (pt)
IL (1) IL297537A (pt)
MX (1) MX2022013378A (pt)
TW (1) TW202140451A (pt)
WO (1) WO2021220120A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022090938A1 (en) * 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
JP2024515338A (ja) 2021-04-08 2024-04-09 ライゼン ファーマシューティカルズ アーゲー ポリ（ａｄｐ－リボース）ポリメラーゼの阻害剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4093448B2 (ja) 1999-01-11 2008-06-04 アグロン・ファーマシューティカルズ・インコーポレーテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
CN100400518C (zh) 2000-10-30 2008-07-09 库多斯药物有限公司 2,3-二氮杂萘酮衍生物
JP2004528376A (ja) 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
EP1633724B1 (en) 2003-03-12 2011-05-04 Kudos Pharmaceuticals Limited Phthalazinone derivatives
MXPA05010563A (es) 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
NZ544989A (en) 2003-07-25 2009-10-30 Cancer Rec Tech Ltd Tricyclic PARP inhibitors
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
EP1791827A1 (en) 2004-08-26 2007-06-06 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
DE602005018506D1 (de) 2004-09-22 2010-02-04 Pfizer Verfahren zur herstellung von poly(adp-ribose)polymeraseinhibitoren
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
GB0428111D0 (en) 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
US20090281086A1 (en) 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
US20090209520A1 (en) 2006-06-15 2009-08-20 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
WO2007144652A2 (en) 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited Parp inhibitors
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
WO2009050469A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one
LT3150610T (lt) 2010-02-12 2019-11-11 Pfizer 8-fluor-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ono druskos ir polimorfai
EP3094752A4 (en) 2014-01-16 2017-08-16 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
KR20210132233A (ko) * 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
EP3182975A4 (en) 2014-08-22 2018-04-18 Clovis Oncology, Inc. High dosage strength tablets of rucaparib
CN105753789B (zh) 2015-04-17 2018-09-25 苏州晶云药物科技有限公司 奥拉帕尼与尿素的共晶及其制备方法
US20170204067A1 (en) 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor
CZ201682A3 (cs) 2016-02-15 2017-08-23 Zentiva, K.S. Solvatované krystalické formy olaparibu, jejich příprava a použití
WO2017153958A1 (en) 2016-03-11 2017-09-14 Lupin Limited Novel polymorphic forms and amorphous form of olaparib
WO2017191562A1 (en) 2016-05-04 2017-11-09 Alembic Pharmaceuticals Limited Process for the preparation of olaparib and polymorphs thereof
WO2018038680A1 (en) 2016-08-24 2018-03-01 Scinopharm Taiwan, Ltd. Processes for preparing olaparib
CN108201536A (zh) 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
DK3615034T3 (da) 2017-04-28 2021-08-23 Akribes Biomedical Gmbh Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling

Also Published As

Publication number Publication date
CL2022002966A1 (es) 2023-04-21
MX2022013378A (es) 2023-02-15
IL297537A (en) 2022-12-01
US20230234938A1 (en) 2023-07-27
CO2022016819A2 (es) 2023-02-16
CN115485271A (zh) 2022-12-16
WO2021220120A1 (en) 2021-11-04
EP4143182A1 (en) 2023-03-08
JP2023524212A (ja) 2023-06-09
TW202140451A (zh) 2021-11-01
AU2021262569A1 (en) 2022-11-24
KR20230002487A (ko) 2023-01-05
CA3176206A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
BR112022008535A2 (pt) Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
BR112022008565A2 (pt) Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
BR112022021521A2 (pt) Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp)
BR112021025034A2 (pt) Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado
JOP20200288A1 (ar) مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
BR112012015745A2 (pt) compostos e métodos para a modulação de quinase, e indicações dos mesmos
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
BR112022020769A2 (pt) Compostos de 2,4-dioxopirimidina de inibição de cd73
BR112022006001A2 (pt) Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
Suzuki et al. Aripiprazole, an antipsychotic and partial dopamine agonist, inhibits cancer stem cells and reverses chemoresistance
Tessema et al. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15
BR112012012694A2 (pt) "derivados de naftiridina e uso dos mesmos como inibidores de cinase"
BRPI0617162B8 (pt) compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
BR112021025102A2 (pt) Derivados de quinazolin-4-ona úteis para o tratamento de doenças e distúrbios associados a braf
BR112018074961A2 (pt) derivados de nucleosídeo de fosforamidato como agentes anticâncer
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112022007719A2 (pt) Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112023022819A2 (pt) Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
BR112022019532A2 (pt) Conjugados de neodegrader